Lattanzi, Simona http://orcid.org/0000-0001-8748-0083
Foschi, Nicoletta
Martellino, Chiara
Audenino, Daniela
Boero, Giovanni
Bonanni, Paolo
Ferlazzo, Edoardo
Chiesa, Valentina
Dainese, Filippo
Piccioli, Marta
Ferrari, Alessandra
Labate, Angelo
Article History
Received: 27 November 2023
Accepted: 9 January 2024
First Online: 1 February 2024
Declarations
:
: Simona Lattanzi has received speaker’s or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, Medscape, and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, Eisai, GW Pharmaceuticals, and Rapport Therapeutics outside the submitted work. Daniela Audenino has received speaker or consultancy fees from Angelini Pharma and UCB Pharma outside the submitted work. Paolo Bonanni has received speaker’s or consultancy fees from EISAI, Angelini, Jazz and Livanova and has served on advisory boards for BIAL, Eisai, Proveca outside the submitted work. Filippo Dainese has received speaker or consultancy fees from Angelini Pharma, Eisai and UCB Pharma outside the submitted work. Valentina Chiesa has received speaker and advisory board honoraria from Angelini Pharma, Eisai Pharma, GW, UCB Pharma outside the submitted work. Filippo Dainese has received speaker or consultancy fees from Angelini Pharma, Eisai and UCB Pharma outside the submitted work. Marta Piccioli has received speaker’s or consultancy fees from Angelini, EISAI, and UCB Pharma outside the submitted work. Nicoletta Foschi, Chiara Martellino, Giovanni Boero, Edoardo Ferlazzo, Alessandra Ferrari, and Angelo Labate have no conflicts of interest to declare.
: The study was approved by the ethical committee of the Marche Polytechnic University, Ancona, Italy (ID CERM 176) and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from each patient or the legal representative for the collection and analysis of data and the dissemination of the results.